Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
9986 | 1038 | 42.4 | 91% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
880 | 10788 | HEREDITARY HEMORRHAGIC TELANGIECTASIA//ENDOGLIN//TGF BETA |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | ALK5 INHIBITOR | Author keyword | 19 | 80% | 1% | 12 |
2 | CELL BASED LUCIFERASE REPORTER ASSAY | Author keyword | 9 | 83% | 0% | 5 |
3 | TGFB1 | Author keyword | 6 | 26% | 2% | 19 |
4 | ALK5 | Author keyword | 4 | 25% | 1% | 15 |
5 | TGF BETA 1 POLYMORPHISMS | Author keyword | 4 | 75% | 0% | 3 |
6 | TGF BETA 1 GENE | Author keyword | 4 | 56% | 0% | 5 |
7 | TGFBR1 | Author keyword | 4 | 25% | 1% | 13 |
8 | SERUM TGF BETA 1 | Author keyword | 3 | 100% | 0% | 3 |
9 | TGF BETA 1 GENE POLYMORPHISM | Author keyword | 3 | 100% | 0% | 3 |
10 | GALUNISERTIB | Author keyword | 3 | 60% | 0% | 3 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ALK5 INHIBITOR | 19 | 80% | 1% | 12 | Search ALK5+INHIBITOR | Search ALK5+INHIBITOR |
2 | CELL BASED LUCIFERASE REPORTER ASSAY | 9 | 83% | 0% | 5 | Search CELL+BASED+LUCIFERASE+REPORTER+ASSAY | Search CELL+BASED+LUCIFERASE+REPORTER+ASSAY |
3 | TGFB1 | 6 | 26% | 2% | 19 | Search TGFB1 | Search TGFB1 |
4 | ALK5 | 4 | 25% | 1% | 15 | Search ALK5 | Search ALK5 |
5 | TGF BETA 1 POLYMORPHISMS | 4 | 75% | 0% | 3 | Search TGF+BETA+1+POLYMORPHISMS | Search TGF+BETA+1+POLYMORPHISMS |
6 | TGF BETA 1 GENE | 4 | 56% | 0% | 5 | Search TGF+BETA+1+GENE | Search TGF+BETA+1+GENE |
7 | TGFBR1 | 4 | 25% | 1% | 13 | Search TGFBR1 | Search TGFBR1 |
8 | SERUM TGF BETA 1 | 3 | 100% | 0% | 3 | Search SERUM+TGF+BETA+1 | Search SERUM+TGF+BETA+1 |
9 | TGF BETA 1 GENE POLYMORPHISM | 3 | 100% | 0% | 3 | Search TGF+BETA+1+GENE+POLYMORPHISM | Search TGF+BETA+1+GENE+POLYMORPHISM |
10 | GALUNISERTIB | 3 | 60% | 0% | 3 | Search GALUNISERTIB | Search GALUNISERTIB |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | TRANSFORMING GROWTH FACTOR BETA 1 GENE | 62 | 41% | 11% | 118 |
2 | TGFBR1 ASTERISK 6A | 45 | 80% | 3% | 28 |
3 | GROWTH FACTOR BETA 1 GENE | 34 | 46% | 5% | 56 |
4 | ALK5 INHIBITOR | 21 | 75% | 1% | 15 |
5 | TUMOR SUSCEPTIBILITY ALLELE | 21 | 90% | 1% | 9 |
6 | TGF BETA 1 GENE | 15 | 50% | 2% | 22 |
7 | ALK5 | 12 | 56% | 1% | 15 |
8 | INT7G24A VARIANT | 11 | 100% | 1% | 6 |
9 | T BETA R I6A | 11 | 100% | 1% | 6 |
10 | I RECEPTOR KINASE | 10 | 47% | 2% | 16 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Targeting the TGF beta signalling pathway in disease | 2012 | 170 | 201 | 23% |
Targeting the TGF beta pathway for cancer therapy | 2015 | 1 | 85 | 35% |
Transforming Growth Factor-beta as a Therapeutic Target in Hepatocellular Carcinoma | 2014 | 22 | 23 | 26% |
The roles of TGF beta in the tumour microenvironment | 2013 | 69 | 142 | 16% |
Complexities of TGF-beta Targeted Cancer Therapy | 2012 | 62 | 125 | 31% |
TGF-beta: Duality of Function Between Tumor Prevention and Carcinogenesis | 2014 | 26 | 191 | 18% |
The polarization of immune cells in the tumour environment by TGF beta | 2010 | 202 | 152 | 20% |
TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression | 2010 | 169 | 82 | 21% |
Transforming growth factor-beta in breast cancer: too much, too late | 2009 | 65 | 65 | 32% |
TGF beta: the molecular Jekyll and Hyde of cancer | 2006 | 593 | 148 | 19% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ONCOL CELL SIGNALING | 2 | 50% | 0.3% | 3 |
2 | LEAD OPTIMIZAT BIOL | 2 | 33% | 0.4% | 4 |
3 | CELL STRUCT MOL BIOL | 1 | 100% | 0.2% | 2 |
4 | GENET COUNSELING CANC UNIT | 1 | 50% | 0.2% | 2 |
5 | MED HEMATOL ONCOLCANC GENET PROGRAM | 1 | 100% | 0.2% | 2 |
6 | ONCOL EARLY CLIN INVEST | 1 | 100% | 0.2% | 2 |
7 | RECEPTOR GROWTH TOR | 1 | 100% | 0.2% | 2 |
8 | CANC BIOLBREAST CANC PROGRAM | 1 | 40% | 0.2% | 2 |
9 | RADIAT SENSITIZAT PROTECT | 1 | 33% | 0.2% | 2 |
10 | ARC 1016B | 1 | 50% | 0.1% | 1 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000233806 | SMAD//SMAD4//SNON |
2 | 0.0000199721 | TGF BETA RECEPTORS//TGF BETA RECEPTOR//MED MED CELL BIOL |
3 | 0.0000156949 | CTHRC1//COLLAGEN TRIPLE HELIX REPEAT CONTAINING 1//CAROTID ARTERY RESTENOSIS |
4 | 0.0000085643 | LTBP//ALPHA V BETA 6//INTEGRIN ALPHAVBETA6 |
5 | 0.0000068809 | ENDOGLIN//CD105//TRC105 |
6 | 0.0000068067 | HUMAN TOXICOL PROGRAM//PROGRAM FREE RAD RADIAT BIOL//BIOQUIM BIOQUIM BIOL MOL |
7 | 0.0000066015 | DERRIFORD COMBINED S//CYTOKINE GENE POLYMORPHISM//CLINICIZZATA CHIRURG 2 |
8 | 0.0000060302 | PHENOTYPE INDUCTION//PHOSPHORYLATED SMAD2//SMAD UBIQUITINATION REGULATORY FACTOR 2 |
9 | 0.0000047391 | IL 1RN//INTERLEUKIN 1 BETA GENE//INTERLEUKIN 1B |
10 | 0.0000047099 | TRANILAST//CORONARY ARTERY ENDOTHELIAL CELL//HUMAN TENONS CAPSULE FIBROBLAST |